Patheon
NDC Database

Patheon

NDC Database

National Drug Code (NDC) records including drug products, NDC numbers, nonproprietary names, dosage forms, strengths, labelers and marketing information.

Drug for Further Processing
  • Total Records 179
  • Latest Marketing Date 2026-05-15
  • Data Source FDA
  • First Marketing Date 1952-12-15
Company Overview

Company

Patheon

Country

U.S.A

Website

Visit Website

Email

doingbusiness@patheon.com

Social Profiles

LinkedIn X / Twitter
Company Snapshot

Patheon

4815 Emperor Blvd., Suite 300
 Durham, NC 27703-8470

U.S.A

www.patheon.com/ doingbusiness@patheon.com View on Map
NDC Records ( 179 records )
1998
24 Dec
Drug for Further Processing NDC: 63285-000

Nonproprietary Name

modafinil

Dosage Form

TABLET

Strength

100 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-000

Substance

MODAFINIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

1998-12-24

End Marketing Date

-

Listing Record Certified Through

2026-12-31

1998
24 Dec
Drug for Further Processing NDC: 63285-001

Nonproprietary Name

modafinil

Dosage Form

TABLET

Strength

200 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-001

Substance

MODAFINIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

1998-12-24

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2006
06 Oct
Drug for Further Processing NDC: 63285-009

Nonproprietary Name

vorinostat

Dosage Form

CAPSULE

Strength

100 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-009

Substance

VORINOSTAT

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2006-10-06

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2004
02 Aug
Drug for Further Processing NDC: 63285-020

Nonproprietary Name

emtricitabine and tenofovir disoproxil fumarate

Dosage Form

TABLET, FILM COATED

Strength

200; 300 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-020

Substance

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2004-08-02

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
01 Jun
Drug for Further Processing NDC: 63285-030

Nonproprietary Name

armodafinil

Dosage Form

TABLET

Strength

50 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-030

Substance

ARMODAFINIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2009-06-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
01 Jun
Drug for Further Processing NDC: 63285-032

Nonproprietary Name

armodafinil

Dosage Form

TABLET

Strength

150 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-032

Substance

ARMODAFINIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2009-06-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
01 Jun
Drug for Further Processing NDC: 63285-033

Nonproprietary Name

armodafinil

Dosage Form

TABLET

Strength

250 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-033

Substance

ARMODAFINIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2009-06-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2011
10 Aug
Drug for Further Processing NDC: 63285-301

Nonproprietary Name

emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate

Dosage Form

TABLET, FILM COATED

Strength

200; 25; 300 mg/1; mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-301

Substance

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2011-08-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
18 Jan
Drug for Further Processing NDC: 63285-735

Nonproprietary Name

TENOFOVIR DISOPROXIL FUMARATE

Dosage Form

TABLET, COATED

Strength

150 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-735

Substance

TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-01-18

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
18 Jan
Drug for Further Processing NDC: 63285-736

Nonproprietary Name

TENOFOVIR DISOPROXIL FUMARATE

Dosage Form

TABLET, COATED

Strength

200 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-736

Substance

TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-01-18

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
18 Jan
Drug for Further Processing NDC: 63285-737

Nonproprietary Name

TENOFOVIR DISOPROXIL FUMARATE

Dosage Form

TABLET, COATED

Strength

250 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-737

Substance

TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-01-18

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
27 Aug
Drug for Further Processing NDC: 63285-738

Nonproprietary Name

elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate

Dosage Form

TABLET, FILM COATED

Strength

150; 150; 200; 300 mg/1; mg/1; mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-738

Substance

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-08-27

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2013
06 Dec
Drug for Further Processing NDC: 63285-752

Nonproprietary Name

sofosbuvir

Dosage Form

TABLET, FILM COATED

Strength

400 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-752

Substance

SOFOSBUVIR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2013-12-06

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
23 Jul
Drug for Further Processing NDC: 63285-753

Nonproprietary Name

idelalisib

Dosage Form

TABLET, FILM COATED

Strength

100 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-753

Substance

IDELALISIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-07-23

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
23 Jul
Drug for Further Processing NDC: 63285-754

Nonproprietary Name

idelalisib

Dosage Form

TABLET, FILM COATED

Strength

150 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-754

Substance

IDELALISIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-07-23

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
01 Oct
Drug for Further Processing NDC: 63285-755

Nonproprietary Name

iloperidone

Dosage Form

KIT

Strength

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-755

Substance

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2009-10-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
01 Oct
Drug for Further Processing NDC: 63285-756

Nonproprietary Name

iloperidone

Dosage Form

KIT

Strength

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-756

Substance

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2009-10-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
16 Apr
Drug for Further Processing NDC: 63285-757

Nonproprietary Name

lenvatinib

Dosage Form

CAPSULE

Strength

10 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-757

Substance

LENVATINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-04-16

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
16 Apr
Drug for Further Processing NDC: 63285-758

Nonproprietary Name

lenvatinib

Dosage Form

CAPSULE

Strength

4 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-758

Substance

LENVATINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-04-16

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
05 Nov
Drug for Further Processing NDC: 63285-763

Nonproprietary Name

elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide fumarate

Dosage Form

TABLET

Strength

150; 150; 200; 10 mg/1; mg/1; mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-763

Substance

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-11-05

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
04 Apr
Drug for Further Processing NDC: 63285-772

Nonproprietary Name

emtricitabine and tenofovir alafenamide fumarate

Dosage Form

TABLET

Strength

200; 25 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-772

Substance

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-04-04

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2016
10 Nov
Drug for Further Processing NDC: 63285-797

Nonproprietary Name

TENOFOVIR ALAFENAMIDE FUMARATE

Dosage Form

TABLET

Strength

25 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-797

Substance

TENOFOVIR ALAFENAMIDE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-11-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
28 Jun
Drug for Further Processing NDC: 63285-799

Nonproprietary Name

velpatasvir and sofosbuvir

Dosage Form

TABLET, FILM COATED

Strength

400; 100 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-799

Substance

SOFOSBUVIR; VELPATASVIR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-06-28

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2018
20 Jul
Drug for Further Processing NDC: 63285-800

Nonproprietary Name

ivosidenib

Dosage Form

TABLET, FILM COATED

Strength

250 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-800

Substance

IVOSIDENIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2018-07-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2018
17 Jul
Drug for Further Processing NDC: 63285-816

Nonproprietary Name

Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide

Dosage Form

TABLET, FILM COATED

Strength

150; 800; 200; 10 mg/1; mg/1; mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-816

Substance

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2018-07-17

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
20 Feb
Drug for Further Processing NDC: 63285-827

Nonproprietary Name

armodafinil

Dosage Form

TABLET

Strength

200 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-827

Substance

ARMODAFINIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2014-02-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
07 Oct
Drug for Further Processing NDC: 63285-828

Nonproprietary Name

ROLAPITANT HYDROCHLORIDE

Dosage Form

TABLET

Strength

90 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-828

Substance

ROLAPITANT HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-10-07

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2005
04 Apr
Drug for Further Processing NDC: 63285-830

Nonproprietary Name

eszopiclone

Dosage Form

TABLET, COATED

Strength

1 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-830

Substance

ESZOPICLONE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2005-04-04

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2005
04 Apr
Drug for Further Processing NDC: 63285-831

Nonproprietary Name

eszopiclone

Dosage Form

TABLET, COATED

Strength

2 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-831

Substance

ESZOPICLONE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2005-04-04

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2005
04 Apr
Drug for Further Processing NDC: 63285-832

Nonproprietary Name

eszopiclone

Dosage Form

TABLET, COATED

Strength

3 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-832

Substance

ESZOPICLONE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2005-04-04

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2017
21 Sep
Drug for Further Processing NDC: 63285-836

Nonproprietary Name

SONIDEGIB PHOSPHATE

Dosage Form

CAPSULE

Strength

200 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-836

Substance

SONIDEGIB PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2017-09-21

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
10 Mar
Drug for Further Processing NDC: 63285-858

Nonproprietary Name

emtricitabine and tenofovir disoproxil fumarate

Dosage Form

TABLET, FILM COATED

Strength

133; 200 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-858

Substance

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-03-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
10 Mar
Drug for Further Processing NDC: 63285-859

Nonproprietary Name

emtricitabine and tenofovir disoproxil fumarate

Dosage Form

TABLET, FILM COATED

Strength

100; 150 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-859

Substance

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-03-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
10 Mar
Drug for Further Processing NDC: 63285-860

Nonproprietary Name

emtricitabine and tenofovir disoproxil fumarate

Dosage Form

TABLET, FILM COATED

Strength

167; 250 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-860

Substance

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-03-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
01 Mar
Drug for Further Processing NDC: 63285-861

Nonproprietary Name

emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate

Dosage Form

TABLET, FILM COATED

Strength

200; 25; 25 mg/1; mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-861

Substance

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-03-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2001
26 Oct
Drug for Further Processing NDC: 63285-872

Nonproprietary Name

tenofovir disoproxil fumarate

Dosage Form

TABLET, COATED

Strength

300 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-872

Substance

TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2001-10-26

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
19 Dec
Drug for Further Processing NDC: 63285-883

Nonproprietary Name

RUCAPARIB CAMSYLATE

Dosage Form

TABLET, FILM COATED

Strength

200 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-883

Substance

RUCAPARIB CAMSYLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-12-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2017
01 May
Drug for Further Processing NDC: 63285-884

Nonproprietary Name

RUCAPARIB CAMSYLATE

Dosage Form

TABLET, FILM COATED

Strength

250 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-884

Substance

RUCAPARIB CAMSYLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2017-05-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
19 Dec
Drug for Further Processing NDC: 63285-885

Nonproprietary Name

RUCAPARIB CAMSYLATE

Dosage Form

TABLET, FILM COATED

Strength

300 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-885

Substance

RUCAPARIB CAMSYLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-12-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
24 Sep
Drug for Further Processing NDC: 63285-889

Nonproprietary Name

cobicistat

Dosage Form

TABLET, FILM COATED

Strength

150 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-889

Substance

COBICISTAT

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-09-24

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
27 Jan
Drug for Further Processing NDC: 63285-904

Nonproprietary Name

relugolix tablet, film coated

Dosage Form

TABLET, FILM COATED

Strength

120 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-904

Substance

RELUGOLIX

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-01-27

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
15 Nov
Drug for Further Processing NDC: 63285-905

Nonproprietary Name

Repotrectinib

Dosage Form

CAPSULE

Strength

40 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-905

Substance

REPOTRECTINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-11-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
01 Dec
Drug for Further Processing NDC: 63285-908

Nonproprietary Name

rivaroxaban

Dosage Form

GRANULE, FOR SUSPENSION

Strength

155 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-908

Substance

RIVAROXABAN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-12-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
05 Oct
Drug for Further Processing NDC: 63285-923

Nonproprietary Name

Iloperidone

Dosage Form

KIT

Strength

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-923

Substance

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2024-10-05

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
27 May
Drug for Further Processing NDC: 63285-924

Nonproprietary Name

iloperidone

Dosage Form

KIT

Strength

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-924

Substance

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2024-05-27

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2025
27 May
Drug for Further Processing NDC: 63285-926

Nonproprietary Name

norethindrone acetate/ethinyl estradiol

Dosage Form

KIT

Strength

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-926

Substance

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-05-27

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2025
27 May
Drug for Further Processing NDC: 63285-927

Nonproprietary Name

norethindrone acetate/ethinyl estradiol

Dosage Form

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE

Strength

20; 1 ug/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-927

Substance

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-05-27

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2025
13 Nov
Drug for Further Processing NDC: 63285-928

Nonproprietary Name

Ziftomenib

Dosage Form

CAPSULE

Strength

200 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-928

Substance

ZIFTOMENIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-11-13

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
28 Mar
Drug for Further Processing NDC: 63285-933

Nonproprietary Name

emtricitabine and tenofovir alafenamide fumarate

Dosage Form

TABLET

Strength

120; 15 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-933

Substance

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-03-28

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2026
04 Feb
Drug for Further Processing NDC: 63285-934

Nonproprietary Name

Repotrectinib

Dosage Form

CAPSULE

Strength

160 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

63285-934

Substance

REPOTRECTINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2026-02-04

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2008
01 Aug
Drug for Further Processing NDC: 66406-0045

Nonproprietary Name

Minoxidil

Dosage Form

TABLET

Strength

2.5 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0045

Substance

MINOXIDIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2008-08-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2008
01 Aug
Drug for Further Processing NDC: 66406-0046

Nonproprietary Name

Minoxidil

Dosage Form

TABLET

Strength

10 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0046

Substance

MINOXIDIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2008-08-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

1952
15 Dec
Drug for Further Processing NDC: 66406-0050

Nonproprietary Name

hydrocortisone

Dosage Form

TABLET

Strength

5 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0050

Substance

HYDROCORTISONE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

1952-12-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

1952
15 Dec
Drug for Further Processing NDC: 66406-0051

Nonproprietary Name

hydrocortisone

Dosage Form

TABLET

Strength

10 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0051

Substance

HYDROCORTISONE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

1952-12-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

1952
15 Dec
Drug for Further Processing NDC: 66406-0052

Nonproprietary Name

hydrocortisone

Dosage Form

TABLET

Strength

20 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0052

Substance

HYDROCORTISONE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

1952-12-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

1995
01 Oct
Drug for Further Processing NDC: 66406-0100

Nonproprietary Name

Famotidine

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0100

Substance

FAMOTIDINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

1995-10-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2003
01 Sep
Drug for Further Processing NDC: 66406-0101

Nonproprietary Name

Famotidine

Dosage Form

TABLET, FILM COATED

Strength

20 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0101

Substance

FAMOTIDINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2003-09-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2004
02 Aug
Drug for Further Processing NDC: 66406-0102

Nonproprietary Name

emtricitabine and tenofovir disoproxil fumarate

Dosage Form

TABLET, FILM COATED

Strength

200; 300 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0102

Substance

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2004-08-02

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2001
26 Oct
Drug for Further Processing NDC: 66406-0103

Nonproprietary Name

TENOFOVIR DISOPROXIL FUMARATE

Dosage Form

TABLET, COATED

Strength

300 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0103

Substance

TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2001-10-26

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2000
01 Sep
Drug for Further Processing NDC: 66406-0106

Nonproprietary Name

colesevelam hydrochloride

Dosage Form

TABLET, FILM COATED

Strength

625 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0106

Substance

COLESEVELAM HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2000-09-01

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2006
15 Sep
Drug for Further Processing NDC: 66406-0200

Nonproprietary Name

posaconazole

Dosage Form

SUSPENSION

Strength

40 mg/mL

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0200

Substance

POSACONAZOLE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2006-09-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
07 Apr
Drug for Further Processing NDC: 66406-0203

Nonproprietary Name

ESLICARBAZEPINE ACETATE

Dosage Form

TABLET

Strength

600 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0203

Substance

ESLICARBAZEPINE ACETATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-04-07

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
07 Apr
Drug for Further Processing NDC: 66406-0204

Nonproprietary Name

ESLICARBAZEPINE ACETATE

Dosage Form

TABLET

Strength

800 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0204

Substance

ESLICARBAZEPINE ACETATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-04-07

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
20 Jun
Drug for Further Processing NDC: 66406-0206

Nonproprietary Name

tedizolid phosphate

Dosage Form

TABLET, COATED

Strength

200 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0206

Substance

TEDIZOLID PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-06-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2005
28 Sep
Drug for Further Processing NDC: 66406-0209

Nonproprietary Name

EMTRICITABINE

Dosage Form

SOLUTION

Strength

10 mg/mL

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0209

Substance

EMTRICITABINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2005-09-28

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2010
01 Dec
Drug for Further Processing NDC: 66406-0211

Nonproprietary Name

dextromethrophan hydrobromide and quinidine sulfate

Dosage Form

CAPSULE, GELATIN COATED

Strength

20; 10 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0211

Substance

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2010-12-01

End Marketing Date

2027-05-31

Listing Record Certified Through

-

2008
24 Apr
Drug for Further Processing NDC: 66406-0219

Nonproprietary Name

methylnaltrexone bromide

Dosage Form

TABLET, FILM COATED

Strength

150 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0219

Substance

METHYLNALTREXONE BROMIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2008-04-24

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
07 Apr
Drug for Further Processing NDC: 66406-0222

Nonproprietary Name

ESLICARBAZEPINE ACETATE

Dosage Form

TABLET

Strength

200 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0222

Substance

ESLICARBAZEPINE ACETATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-04-07

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
25 Mar
Drug for Further Processing NDC: 66406-0240

Nonproprietary Name

APREMILAST

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0240

Substance

APREMILAST

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-03-25

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
25 Mar
Drug for Further Processing NDC: 66406-0241

Nonproprietary Name

APREMILAST

Dosage Form

TABLET, FILM COATED

Strength

20 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0241

Substance

APREMILAST

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-03-25

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
25 Mar
Drug for Further Processing NDC: 66406-0242

Nonproprietary Name

APREMILAST

Dosage Form

TABLET, FILM COATED

Strength

30 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0242

Substance

APREMILAST

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-03-25

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2013
17 Jan
Drug for Further Processing NDC: 66406-0244

Nonproprietary Name

OXCARBAZEPINE

Dosage Form

TABLET

Strength

300 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0244

Substance

OXCARBAZEPINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2013-01-17

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2013
17 Jan
Drug for Further Processing NDC: 66406-0245

Nonproprietary Name

OXCARBAZEPINE

Dosage Form

TABLET

Strength

600 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0245

Substance

OXCARBAZEPINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2013-01-17

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2013
17 Jan
Drug for Further Processing NDC: 66406-0246

Nonproprietary Name

OXCARBAZEPINE

Dosage Form

TABLET

Strength

150 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0246

Substance

OXCARBAZEPINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2013-01-17

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2010
01 Dec
Drug for Further Processing NDC: 66406-0247

Nonproprietary Name

dextromethorphan hydrobromide and quinidine sulfate

Dosage Form

CAPSULE, GELATIN COATED

Strength

20; 10 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0247

Substance

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2010-12-01

End Marketing Date

2027-05-31

Listing Record Certified Through

-

2018
07 Feb
Drug for Further Processing NDC: 66406-0273

Nonproprietary Name

bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate

Dosage Form

TABLET

Strength

50; 200; 25 mg/1; mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0273

Substance

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2018-02-07

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
31 Mar
Drug for Further Processing NDC: 66406-0275

Nonproprietary Name

felodipine

Dosage Form

TABLET, EXTENDED RELEASE

Strength

2.5 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0275

Substance

FELODIPINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2009-03-31

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2011
15 Dec
Drug for Further Processing NDC: 66406-0276

Nonproprietary Name

felodipine

Dosage Form

TABLET, EXTENDED RELEASE

Strength

5 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0276

Substance

FELODIPINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2011-12-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2011
15 Dec
Drug for Further Processing NDC: 66406-0277

Nonproprietary Name

felodipine

Dosage Form

TABLET, EXTENDED RELEASE

Strength

10 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0277

Substance

FELODIPINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2011-12-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2026
15 May
Drug for Further Processing NDC: 66406-0280

Nonproprietary Name

TETRAFERRIC TRICITRATE DECAHYDRATE

Dosage Form

TABLET, COATED

Strength

210 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0280

Substance

TETRAFERRIC TRICITRATE DECAHYDRATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2026-05-15

End Marketing Date

-

Listing Record Certified Through

2027-12-31

1952
15 Dec
Drug for Further Processing NDC: 66406-0285

Nonproprietary Name

hydrocortisone

Dosage Form

TABLET

Strength

10 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0285

Substance

HYDROCORTISONE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

1952-12-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2003
24 Jun
Drug for Further Processing NDC: 66406-0287

Nonproprietary Name

atazanavir sulfate

Dosage Form

CAPSULE, GELATIN COATED

Strength

200 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0287

Substance

ATAZANAVIR SULFATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2003-06-24

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2003
24 Jun
Drug for Further Processing NDC: 66406-0288

Nonproprietary Name

atazanavir sulfate

Dosage Form

CAPSULE, GELATIN COATED

Strength

300 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0288

Substance

ATAZANAVIR SULFATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2003-06-24

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
29 Jan
Drug for Further Processing NDC: 66406-0289

Nonproprietary Name

atazanavir sulfate and cobicistat

Dosage Form

TABLET

Strength

300; 150 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0289

Substance

ATAZANAVIR SULFATE; COBICISTAT

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-01-29

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Feb
Drug for Further Processing NDC: 66406-0300

Nonproprietary Name

lumateperone

Dosage Form

CAPSULE

Strength

42 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0300

Substance

LUMATEPERONE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-02-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2019
25 Nov
Drug for Further Processing NDC: 66406-0301

Nonproprietary Name

Voxelotor

Dosage Form

TABLET, FILM COATED

Strength

500 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0301

Substance

VOXELOTOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2019-11-25

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
02 Feb
Drug for Further Processing NDC: 66406-0323

Nonproprietary Name

SITAGLIPTIN PHOSPHATE and METFORMIN HYDROCHLORIDE

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

1000; 50 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0323

Substance

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-02-02

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
02 Feb
Drug for Further Processing NDC: 66406-0324

Nonproprietary Name

SITAGLIPTIN PHOSPHATE and METFORMIN HYDROCHLORIDE

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

1000; 100 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0324

Substance

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-02-02

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
02 Feb
Drug for Further Processing NDC: 66406-0325

Nonproprietary Name

SITAGLIPTIN PHOSPHATE and METFORMIN HYDROCHLORIDE

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

500; 50 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0325

Substance

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-02-02

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
07 Apr
Drug for Further Processing NDC: 66406-0327

Nonproprietary Name

eslicarbazepine acetate

Dosage Form

TABLET

Strength

400 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0327

Substance

ESLICARBAZEPINE ACETATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-04-07

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2005
29 Mar
Drug for Further Processing NDC: 66406-0331

Nonproprietary Name

entecavir

Dosage Form

SOLUTION

Strength

0.05 mg/mL

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0331

Substance

ENTECAVIR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2005-03-29

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
23 Dec
Drug for Further Processing NDC: 66406-0332

Nonproprietary Name

molnupiravir

Dosage Form

CAPSULE

Strength

200 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0332

Substance

MOLNUPIRAVIR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-12-23

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
17 Dec
Drug for Further Processing NDC: 66406-0333

Nonproprietary Name

voxelotor

Dosage Form

TABLET, FOR SUSPENSION

Strength

300 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0333

Substance

VOXELOTOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-12-17

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
05 Nov
Drug for Further Processing NDC: 66406-0334

Nonproprietary Name

Oteseconazole

Dosage Form

CAPSULE, GELATIN COATED

Strength

150 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0334

Substance

OTESECONAZOLE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-11-05

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
18 Aug
Drug for Further Processing NDC: 66406-0336

Nonproprietary Name

DEXTROMETHORPHAN HYDROBROMIDE and BUPROPION HYDROCHLORIDE

Dosage Form

TABLET, MULTILAYER, EXTENDED RELEASE

Strength

105; 45 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0336

Substance

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-08-18

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2022
29 Sep
Drug for Further Processing NDC: 66406-0338

Nonproprietary Name

sodium phenylbutyrate and ursodoxicoltaurine

Dosage Form

POWDER

Strength

3; 1 g/14600g; g/14600g

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0338

Substance

SODIUM PHENYLBUTYRATE; TAURURSODIOL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-09-29

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
14 Oct
Drug for Further Processing NDC: 66406-0442

Nonproprietary Name

Voxelotor

Dosage Form

TABLET, FILM COATED

Strength

300 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0442

Substance

VOXELOTOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-10-14

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
11 Mar
Drug for Further Processing NDC: 66406-0446

Nonproprietary Name

Famotidine

Dosage Form

TABLET, FILM COATED

Strength

20 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0446

Substance

FAMOTIDINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2024-03-11

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2025
15 Sep
Drug for Further Processing NDC: 66406-0460

Nonproprietary Name

acoramidis hydrochloride

Dosage Form

TABLET, FILM COATED

Strength

356 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0460

Substance

ACORAMIDIS HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-09-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

1995
01 Oct
Drug for Further Processing NDC: 66406-0461

Nonproprietary Name

famotidine

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0461

Substance

FAMOTIDINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

1995-10-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
13 Jan
Drug for Further Processing NDC: 66406-0462

Nonproprietary Name

emtricitabine and tenofovir disoproxil fumarate

Dosage Form

TABLET, FILM COATED

Strength

100; 150 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0462

Substance

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-01-13

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2023
13 Jan
Drug for Further Processing NDC: 66406-0463

Nonproprietary Name

emtricitabine and tenofovir disoproxil fumarate

Dosage Form

TABLET, FILM COATED

Strength

133; 200 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0463

Substance

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-01-13

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2023
13 Jan
Drug for Further Processing NDC: 66406-0464

Nonproprietary Name

emtricitabine and tenofovir disoproxil fumarate

Dosage Form

TABLET, FILM COATED

Strength

167; 250 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0464

Substance

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-01-13

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2026
11 Mar
Drug for Further Processing NDC: 66406-0465

Nonproprietary Name

sirolimus solution

Dosage Form

SOLUTION

Strength

1 mg/mL

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0465

Substance

SIROLIMUS

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2026-03-11

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2026
01 May
Drug for Further Processing NDC: 66406-0467

Nonproprietary Name

DEXTROMETHORPHAN HYDROBROMIDE and BUPROPION HYDROCHLORIDE

Dosage Form

TABLET, MULTILAYER, EXTENDED RELEASE

Strength

105; 30 mg/1; mg/1

Labeler

Patheon Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

66406-0467

Substance

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2026-05-01

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2005
01 Jun
Drug for Further Processing NDC: 68225-013

Nonproprietary Name

Tigecycline

Dosage Form

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength

50 mg/1

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-013

Substance

TIGECYCLINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2005-06-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2008
09 Jun
Drug for Further Processing NDC: 68225-040

Nonproprietary Name

Thrombin, topical (Recombinant)

Dosage Form

POWDER, FOR SOLUTION

Strength

1000 [iU]/mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-040

Substance

THROMBIN ALFA

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2008-06-09

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2000
15 Dec
Drug for Further Processing NDC: 68225-041

Nonproprietary Name

bivalirudin

Dosage Form

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength

250 mg/5mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-041

Substance

BIVALIRUDIN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2000-12-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2007
02 Apr
Drug for Further Processing NDC: 68225-042

Nonproprietary Name

eculizumab

Dosage Form

INJECTION, SOLUTION, CONCENTRATE

Strength

300 mg/30mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-042

Substance

ECULIZUMAB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2007-04-02

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2008
20 Apr
Drug for Further Processing NDC: 68225-045

Nonproprietary Name

certolizumab pegol

Dosage Form

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength

200 mg/mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-045

Substance

CERTOLIZUMAB PEGOL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2008-04-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
01 Sep
Drug for Further Processing NDC: 68225-051

Nonproprietary Name

oritavancin

Dosage Form

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength

400 mg/1

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-051

Substance

ORITAVANCIN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-09-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2003
12 Sep
Drug for Further Processing NDC: 68225-052

Nonproprietary Name

Daptomycin

Dosage Form

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength

500 mg/10mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-052

Substance

DAPTOMYCIN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2003-09-12

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
26 May
Drug for Further Processing NDC: 68225-057

Nonproprietary Name

lacosamide

Dosage Form

INJECTION

Strength

10 mg/mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-057

Substance

LACOSAMIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CV

Start Marketing Date

2009-05-26

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2017
12 May
Drug for Further Processing NDC: 68225-059

Nonproprietary Name

coagulation factor IX (recombinant)

Dosage Form

POWDER

Strength

500 [iU]/5mL

Labeler

Patheon Italia S.P.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-059

Substance

COAGULATION FACTOR IX RECOMBINANT HUMAN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2017-05-12

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2017
12 May
Drug for Further Processing NDC: 68225-060

Nonproprietary Name

coagulation factor IX (recombinant)

Dosage Form

POWDER

Strength

1000 [iU]/5mL

Labeler

Patheon Italia S.P.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-060

Substance

COAGULATION FACTOR IX RECOMBINANT HUMAN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2017-05-12

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2017
12 May
Drug for Further Processing NDC: 68225-061

Nonproprietary Name

coagulation factor IX (recombinant)

Dosage Form

POWDER

Strength

1500 [iU]/5mL

Labeler

Patheon Italia S.P.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-061

Substance

COAGULATION FACTOR IX RECOMBINANT HUMAN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2017-05-12

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
20 Jun
Drug for Further Processing NDC: 68225-066

Nonproprietary Name

tedizolid phosphate

Dosage Form

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength

200 mg/4mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-066

Substance

TEDIZOLID PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-06-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
15 Dec
Drug for Further Processing NDC: 68225-067

Nonproprietary Name

Anakinra

Dosage Form

INJECTION, SOLUTION

Strength

100 mg/.67mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-067

Substance

ANAKINRA

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2009-12-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2025
22 Feb
Drug for Further Processing NDC: 68225-250

Nonproprietary Name

ustekinumab-ttwe

Dosage Form

INJECTION, SOLUTION

Strength

45 mg/.5mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-250

Substance

USTEKINUMAB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-02-22

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2025
22 Feb
Drug for Further Processing NDC: 68225-251

Nonproprietary Name

ustekinumab-ttwe

Dosage Form

INJECTION, SOLUTION

Strength

90 mg/mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-251

Substance

USTEKINUMAB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-02-22

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2025
22 Feb
Drug for Further Processing NDC: 68225-253

Nonproprietary Name

ustekinumab-ttwe

Dosage Form

INJECTION, SOLUTION

Strength

130 mg/26mL

Labeler

Patheon Italia S.p.A

Marketing Category

DRUG FOR FURTHER PROCESSING

68225-253

Substance

USTEKINUMAB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-02-22

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
27 May
Drug for Further Processing NDC: 67651-0222

Nonproprietary Name

linagliptin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

2.5; 1000 mg/1; mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0222

Substance

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-05-27

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
27 May
Drug for Further Processing NDC: 67651-0223

Nonproprietary Name

linagliptin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

5; 1000 mg/1; mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0223

Substance

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-05-27

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
31 Jan
Drug for Further Processing NDC: 67651-0263

Nonproprietary Name

ivacaftor

Dosage Form

TABLET, FILM COATED

Strength

150 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0263

Substance

IVACAFTOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-01-31

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2013
20 Dec
Drug for Further Processing NDC: 67651-0274

Nonproprietary Name

RALTEGRAVIR POTASSIUM

Dosage Form

GRANULE, FOR SUSPENSION

Strength

214.4 mg/kg

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0274

Substance

RALTEGRAVIR POTASSIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2013-12-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2011
21 Dec
Drug for Further Processing NDC: 67651-0275

Nonproprietary Name

RALTEGRAVIR POTASSIUM

Dosage Form

TABLET, CHEWABLE

Strength

25 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0275

Substance

RALTEGRAVIR POTASSIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2011-12-21

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2011
21 Dec
Drug for Further Processing NDC: 67651-0276

Nonproprietary Name

RALTEGRAVIR POTASSIUM

Dosage Form

TABLET, CHEWABLE

Strength

100 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0276

Substance

RALTEGRAVIR POTASSIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2011-12-21

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
21 Aug
Drug for Further Processing NDC: 67651-0294

Nonproprietary Name

VIGABATRIN

Dosage Form

POWDER, FOR SOLUTION

Strength

500 mg/.0005kg

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0294

Substance

VIGABATRIN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2009-08-21

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
04 Apr
Drug for Further Processing NDC: 67651-0307

Nonproprietary Name

TASIMELTEON

Dosage Form

CAPSULE

Strength

20 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0307

Substance

TASIMELTEON

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-04-04

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2010
01 Aug
Drug for Further Processing NDC: 67651-0308

Nonproprietary Name

doxepin hydrochloride

Dosage Form

TABLET

Strength

3 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0308

Substance

DOXEPIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2010-08-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2010
01 Aug
Drug for Further Processing NDC: 67651-0309

Nonproprietary Name

doxepin hydrochloride

Dosage Form

TABLET

Strength

6 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0309

Substance

DOXEPIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2010-08-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2018
28 Jun
Drug for Further Processing NDC: 67651-0325

Nonproprietary Name

pimavanserin tartrate

Dosage Form

TABLET, COATED

Strength

10 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0325

Substance

PIMAVANSERIN TARTRATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2018-06-28

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2018
02 Nov
Drug for Further Processing NDC: 67651-0327

Nonproprietary Name

sufentanil

Dosage Form

TABLET

Strength

30 ug/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0327

Substance

SUFENTANIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CII

Start Marketing Date

2018-11-02

End Marketing Date

2028-08-31

Listing Record Certified Through

-

2019
07 Jan
Drug for Further Processing NDC: 67651-0328

Nonproprietary Name

amifampridine phosphate

Dosage Form

TABLET

Strength

10 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0328

Substance

AMIFAMPRIDINE PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2019-01-07

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2018
14 Dec
Drug for Further Processing NDC: 67651-0330

Nonproprietary Name

PRUCALOPRIDE SUCCINATE

Dosage Form

TABLET, FILM COATED

Strength

1 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0330

Substance

PRUCALOPRIDE SUCCINATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2018-12-14

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2018
14 Dec
Drug for Further Processing NDC: 67651-0331

Nonproprietary Name

PRUCALOPRIDE SUCCINATE

Dosage Form

TABLET, FILM COATED

Strength

2 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0331

Substance

PRUCALOPRIDE SUCCINATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2018-12-14

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2019
12 Sep
Drug for Further Processing NDC: 67651-0335

Nonproprietary Name

tenapanor hydrochloride

Dosage Form

TABLET

Strength

53.2 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0335

Substance

TENAPANOR HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2019-09-12

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2018
28 Jun
Drug for Further Processing NDC: 67651-0336

Nonproprietary Name

pimavanserin tartrate

Dosage Form

CAPSULE

Strength

34 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0336

Substance

PIMAVANSERIN TARTRATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2018-06-28

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
16 Apr
Drug for Further Processing NDC: 67651-0343

Nonproprietary Name

selumetinib

Dosage Form

CAPSULE

Strength

10 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0343

Substance

SELUMETINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-04-16

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
16 Apr
Drug for Further Processing NDC: 67651-0344

Nonproprietary Name

selumetinib

Dosage Form

CAPSULE

Strength

25 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0344

Substance

SELUMETINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-04-16

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
18 Oct
Drug for Further Processing NDC: 67651-0363

Nonproprietary Name

AVACOPAN

Dosage Form

CAPSULE

Strength

10 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0363

Substance

AVACOPAN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-10-18

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
18 Oct
Drug for Further Processing NDC: 67651-0364

Nonproprietary Name

AVACOPAN

Dosage Form

CAPSULE

Strength

10 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0364

Substance

AVACOPAN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-10-18

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
23 Dec
Drug for Further Processing NDC: 67651-0365

Nonproprietary Name

molnupiravir

Dosage Form

CAPSULE

Strength

200 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0365

Substance

MOLNUPIRAVIR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-12-23

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
27 Sep
Drug for Further Processing NDC: 67651-0375

Nonproprietary Name

Omadacycline

Dosage Form

TABLET, FILM COATED

Strength

150 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0375

Substance

OMADACYCLINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-09-27

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
17 Oct
Drug for Further Processing NDC: 67651-0380

Nonproprietary Name

tenapanor

Dosage Form

TABLET, FILM COATED

Strength

21.3 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0380

Substance

TENAPANOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-10-17

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
17 Oct
Drug for Further Processing NDC: 67651-0381

Nonproprietary Name

tenapanor

Dosage Form

TABLET, FILM COATED

Strength

31.9 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0381

Substance

TENAPANOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-10-17

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
20 Jan
Drug for Further Processing NDC: 67651-0382

Nonproprietary Name

Suvorexant

Dosage Form

TABLET, FILM COATED

Strength

5 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0382

Substance

SUVOREXANT

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2024-01-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
20 Jan
Drug for Further Processing NDC: 67651-0383

Nonproprietary Name

Suvorexant

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0383

Substance

SUVOREXANT

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2024-01-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
20 Jan
Drug for Further Processing NDC: 67651-0384

Nonproprietary Name

Suvorexant

Dosage Form

TABLET, FILM COATED

Strength

15 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0384

Substance

SUVOREXANT

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2024-01-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
20 Jan
Drug for Further Processing NDC: 67651-0385

Nonproprietary Name

Suvorexant

Dosage Form

TABLET, FILM COATED

Strength

20 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0385

Substance

SUVOREXANT

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CIV

Start Marketing Date

2024-01-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
19 Feb
Drug for Further Processing NDC: 67651-0386

Nonproprietary Name

lisdexamfetamine dimesylate

Dosage Form

CAPSULE

Strength

20 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0386

Substance

LISDEXAMFETAMINE DIMESYLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CII

Start Marketing Date

2024-02-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
19 Feb
Drug for Further Processing NDC: 67651-0387

Nonproprietary Name

lisdexamfetamine dimesylate

Dosage Form

CAPSULE

Strength

30 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0387

Substance

LISDEXAMFETAMINE DIMESYLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CII

Start Marketing Date

2024-02-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
19 Feb
Drug for Further Processing NDC: 67651-0388

Nonproprietary Name

lisdexamfetamine dimesylate

Dosage Form

CAPSULE

Strength

40 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0388

Substance

LISDEXAMFETAMINE DIMESYLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

CII

Start Marketing Date

2024-02-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
25 Sep
Drug for Further Processing NDC: 67651-0393

Nonproprietary Name

tenapanor

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0393

Substance

TENAPANOR HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-09-25

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
06 Jul
Drug for Further Processing NDC: 67651-0394

Nonproprietary Name

naproxen and esomeprazole magnesium

Dosage Form

TABLET, DELAYED RELEASE

Strength

20; 375 mg/1; mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0394

Substance

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-07-06

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
08 Jul
Drug for Further Processing NDC: 67651-0395

Nonproprietary Name

naproxen and esomeprazole magnesium

Dosage Form

TABLET, DELAYED RELEASE

Strength

20; 500 mg/1; mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0395

Substance

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-07-08

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
09 Aug
Drug for Further Processing NDC: 67651-0396

Nonproprietary Name

vanzacaftor, tezacaftor, and deutivacaftor

Dosage Form

TABLET, FILM COATED

Strength

50; 20; 4 mg/1; mg/1; mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0396

Substance

DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2024-08-09

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
04 Aug
Drug for Further Processing NDC: 67651-0397

Nonproprietary Name

vanzacaftor, tezacaftor, and deutivacaftor

Dosage Form

TABLET, FILM COATED

Strength

125; 50; 10 mg/1; mg/1; mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0397

Substance

DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2024-08-04

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
26 Apr
Drug for Further Processing NDC: 67651-0404

Nonproprietary Name

elexacaftor, tezacaftor, and ivacaftor

Dosage Form

TABLET, FILM COATED

Strength

50; 37.5; 25 mg/1; mg/1; mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0404

Substance

ELEXACAFTOR; IVACAFTOR; TEZACAFTOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2024-04-26

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2024
13 Aug
Drug for Further Processing NDC: 67651-0405

Nonproprietary Name

elexacaftor, tezacaftor, and ivacaftor

Dosage Form

TABLET, FILM COATED

Strength

100; 75; 50 mg/1; mg/1; mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0405

Substance

ELEXACAFTOR; IVACAFTOR; TEZACAFTOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2024-08-13

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
27 Aug
Drug for Further Processing NDC: 67651-0406

Nonproprietary Name

pitolisant hydrochloride

Dosage Form

TABLET, FILM COATED

Strength

4.45 mg/1

Labeler

Patheon Pharmaceuticals Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

67651-0406

Substance

PITOLISANT HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-08-27

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2007
30 Mar
Drug for Further Processing NDC: 55370-001

Nonproprietary Name

SITAGLIPTIN and METFORMIN HYDROCHLORIDE

Dosage Form

TABLET, FILM COATED

Strength

500; 50 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-001

Substance

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2007-03-30

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2007
30 Mar
Drug for Further Processing NDC: 55370-002

Nonproprietary Name

SITAGLIPTIN and METFORMIN HYDROCHLORIDE

Dosage Form

TABLET, FILM COATED

Strength

850; 50 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-002

Substance

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2007-03-30

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2007
30 Mar
Drug for Further Processing NDC: 55370-003

Nonproprietary Name

SITAGLIPTIN and METFORMIN HYDROCHLORIDE

Dosage Form

TABLET, FILM COATED

Strength

1000; 50 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-003

Substance

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2007-03-30

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2007
30 Mar
Drug for Further Processing NDC: 55370-006

Nonproprietary Name

SITAGLIPTIN and METFORMIN HYDROCHLORIDE

Dosage Form

TABLET, FILM COATED

Strength

850; 50 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

EXPORT ONLY

55370-006

Substance

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2007-03-30

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
01 Dec
Drug for Further Processing NDC: 55370-790

Nonproprietary Name

loratadine and pseudoephedrine sulfate

Dosage Form

TABLET, EXTENDED RELEASE

Strength

10; 240 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-790

Substance

LORATADINE; PSEUDOEPHEDRINE SULFATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2009-12-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
12 Sep
Drug for Further Processing NDC: 55370-794

Nonproprietary Name

empagliflozin and metformin hydrochloride

Dosage Form

TABLET

Strength

5; 500 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-794

Substance

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-09-12

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2015
12 Sep
Drug for Further Processing NDC: 55370-795

Nonproprietary Name

empagliflozin and metformin hydrochloride

Dosage Form

TABLET

Strength

5; 1000 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-795

Substance

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-09-12

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2015
12 Sep
Drug for Further Processing NDC: 55370-796

Nonproprietary Name

empagliflozin and metformin hydrochloride

Dosage Form

TABLET

Strength

12.5; 500 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-796

Substance

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-09-12

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2015
12 Sep
Drug for Further Processing NDC: 55370-797

Nonproprietary Name

empagliflozin and metformin hydrochloride

Dosage Form

TABLET

Strength

12.5; 1000 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-797

Substance

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-09-12

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2015
12 Sep
Drug for Further Processing NDC: 55370-799

Nonproprietary Name

empagliflozin and metformin hydrochloride

Dosage Form

TABLET

Strength

5; 850 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-799

Substance

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-09-12

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
12 Sep
Drug for Further Processing NDC: 55370-800

Nonproprietary Name

empagliflozin and metformin hydrochloride

Dosage Form

TABLET

Strength

12.5; 850 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-800

Substance

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-09-12

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
12 Sep
Drug for Further Processing NDC: 55370-823

Nonproprietary Name

empagliflozin and metformin hydrochloride

Dosage Form

TABLET

Strength

12.5; 1000 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-823

Substance

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-09-12

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2016
27 Aug
Drug for Further Processing NDC: 55370-824

Nonproprietary Name

Metformin Hydrochloride

Dosage Form

POWDER

Strength

0.98 kg/kg

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-824

Substance

METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-08-27

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2025
01 Jan
Drug for Further Processing NDC: 55370-825

Nonproprietary Name

empagliflozin and metformin hydrochloride

Dosage Form

TABLET

Strength

5; 1000 mg/1; mg/1

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-825

Substance

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-01-01

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2016
27 Jul
Drug for Further Processing NDC: 55370-826

Nonproprietary Name

Metformin Hydrochloride

Dosage Form

POWDER

Strength

0.88 kg/kg

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-826

Substance

METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-07-27

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2016
04 Aug
Drug for Further Processing NDC: 55370-827

Nonproprietary Name

Metformin Hydrochloride

Dosage Form

POWDER

Strength

0.96 kg/kg

Labeler

Patheon Puerto Rico, Inc.

Marketing Category

DRUG FOR FURTHER PROCESSING

55370-827

Substance

METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-08-04

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2017
06 Oct
Drug for Further Processing NDC: 52945-068

Nonproprietary Name

triamcinolone acetonide

Dosage Form

INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE

Strength

32 mg/1

Labeler

Patheon UK Limited

Marketing Category

DRUG FOR FURTHER PROCESSING

52945-068

Substance

TRIAMCINOLONE ACETONIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2017-10-06

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
01 Jan
Drug for Further Processing NDC: 52945-069

Nonproprietary Name

bupivacaine

Dosage Form

INJECTION, SUSPENSION, LIPOSOMAL

Strength

13.3 mg/mL

Labeler

Patheon UK Limited

Marketing Category

DRUG FOR FURTHER PROCESSING

52945-069

Substance

BUPIVACAINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

Related Databases
  • FDA Inspections
    60 View
  • EDQM CEP
    4 View
  • KDMF
    0 View
  • Japan DMF
    0 View
  • Eudra GMP
    4 View
  • NDC Database
    179 View
  • FDA Approved Drugs Database
    0 View
  • Drug Prices in Switzerland
    0 View
NDC Type Breakdown
179 total
  • Drug for Further Processing
Official Source

NDC data is based on publicly available National Drug Code information from the U.S. Food and Drug Administration (FDA).

Visit FDA NDC Directory
NDC Record Details Preview

Explore important National Drug Code information available in the records above.

NDC

63285-000

Nonproprietary Name

modafinil

Labeler

Patheon Inc.

Dosage Form

TABLET

FDA NDC Data

National Drug Code information

Regular Updates

Data maintained from official sources

Structured Database

Searchable pharmaceutical data

Reliable Data

Organized NDC records

NDC data is based on publicly available U.S. Food and Drug Administration (FDA) National Drug Code information.

Create a New Buying Request

Fields marked with * are mandatory.

Please enter quantity.
Please select a unit.
Please select quality standard.
Please select request type.
Please provide product specifications.
Please enter additional details.
Please select shipping preference.
Notice: By submitting this buying request, the provided product details and requirements may be published publicly on our marketplace.
Login to Submit